Pfizer’s keys to juggling 8 U.S. launches? Organization, accountability, clear goals
Think you’re busy? Take a look at Pfizer’s commercial team for oncology, which is currently launching four new drugs, three new indications for older drugs, and a biosimilar. And that’s just in the U.S. It’s taken some serious internal organizing on Pfizer’s part, but so far managing the multiple rollouts has been “done very well,”… Read More »